Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Brain damage after intrathecal methotrexate.

B Smith

    Journal of Neurology, Neurosurgery, and Psychiatry
    |August 1, 1975
    PubMed
    Summary
    This summary is machine-generated.

    Intrathecal methotrexate can cause severe brain damage in leukemia patients, including oligodendrocyte destruction and astrocytosis. Some patients died from this therapy, highlighting significant treatment risks.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Psychotropic drugs in breast milk: no evidence for adverse effects on prepulse modulation of startle reflex or on cognitive level in infants.

    Developmental psychobiology·1998
    Same author

    An externally powered, multichannel, implantable stimulator-telemeter for control of paralyzed muscle.

    IEEE transactions on bio-medical engineering·1998
    Same author

    Fluoxetine in breast-milk and developmental outcome of breast-fed infants.

    The British journal of psychiatry : the journal of mental science·1998
    Same author

    Human brain tumors and exposure to metal and non-metal elements: a case-control study.

    Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer·1998
    Same author

    Rehospitalisation for asthma within 12 months: unequal rates on the basis of gender in two hospitals.

    Australian and New Zealand journal of medicine·1998
    Same author

    Asthma prevalence, morbidity and management practices in South Australia, 1992-1995.

    Australian and New Zealand journal of medicine·1998
    Same journal

    Characteristics and outcomes in electric scooter-related traumatic brain injuries in Helsinki.

    Journal of neurology, neurosurgery, and psychiatry·2026
    Same journal

    Chronological ageing and ovarian reserve in MS: insights from anti-Müllerian hormone and disability progression.

    Journal of neurology, neurosurgery, and psychiatry·2026
    Same journal

    Durable fluoropolymer drug-eluting stent versus bare-metal stent for the prevention of intracranial in-stent restenosis.

    Journal of neurology, neurosurgery, and psychiatry·2026
    Same journal

    Correction: <i>How well do plasma Alzheimer's disease biomarkers reflect the CSF amyloid status?</i>

    Journal of neurology, neurosurgery, and psychiatry·2026
    Same journal

    Correction: <i>First presentation with neuropsychiatric symptoms in autosomal dominant Alzheimer's disease: the Dominantly Inherited Alzheimer's Network Study</i>.

    Journal of neurology, neurosurgery, and psychiatry·2026
    Same journal

    Correction: <i>Clinical utility of cerebrospinal fluid biomarkers in the evaluation of cognitive impairment: a systematic review and meta-analysis</i>.

    Journal of neurology, neurosurgery, and psychiatry·2026
    See all related articles

    Area of Science:

    • Neuropathology
    • Neuro-oncology
    • Toxicology

    Background:

    • Intrathecal methotrexate is a chemotherapy delivery method used for leukemia.
    • Understanding the neurological side effects of this treatment is crucial for patient safety.

    Observation:

    • Histological examination of brains from leukemia patients treated with intrathecal methotrexate versus those without.
    • Assessed neurological damage, specifically focusing on oligodendrocytes and astrocytosis.

    Findings:

    • Methotrexate therapy led to significant oligodendrocyte destruction, varying in severity.
    • Severe astrocytosis was observed in patients who survived long enough post-treatment.
    • Three patients in the methotrexate group appeared to have died as a direct result of the therapy.

    Related Experiment Videos

    Implications:

    • Intrathecal methotrexate poses serious risks of neurotoxicity in leukemia patients.
    • Findings necessitate careful monitoring and potential alternative treatment strategies.
    • Further research into mitigating methotrexate-induced brain injury is warranted.